Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Brian M Calimlim"'
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
Autor:
Andrew Blauvelt, Kilian Eyerich, Alan D. Irvine, Marjolein de Bruin-Weller, Shawn G. Kwatra, Melinda Gooderham, Brian Kim, Brian M. Calimlim, Wan-Ju Lee, Eliza M. Raymundo, Yingyi Liu, Sarah Ofori, Andrew M. Platt, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2621-2630 (2024)
Abstract Introduction Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients’ quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment ve
Externí odkaz:
https://doaj.org/article/f20cd55b09a34e87a0a91cfbd7f735cf
Autor:
April W. Armstrong, H. Chih-Ho Hong, Brian M. Calimlim, Marric G. Buessing, Marjorie M. Crowell, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2457-2465 (2024)
Abstract Introduction Efficacy of upadacitinib has been assessed in trials including Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397). Measure Up 1 and 2 assessed efficacy of upadacitinib 30 mg and upadacitinib 15 mg
Externí odkaz:
https://doaj.org/article/c50f79e2bc6f4b5e8459d5588f42735c
Autor:
Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein S. de Bruin-Weller, Sonja Ständer, Andrew E. Pink, Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1127-1144 (2024)
Abstract Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on p
Externí odkaz:
https://doaj.org/article/d13086b1bc984adeabc8518d220ee7d9
Autor:
Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-repo
Externí odkaz:
https://doaj.org/article/e139efa252da462c88ff16c82b4fb9cd
Autor:
Shawn G. Kwatra, Marjolein de Bruin-Weller, Jonathan I. Silverberg, Peter Lio, Mette Deleuran, Handan Aydin, Brian M. Calimlim, Michael C. Lane, Yingyi Liu, Sarah Ofori, Stephan Weidinger
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
A treat-to-target approach was recently developed to guide systemic treatment for adults with atopic dermatitis (AD). Recommendations outlined criteria for a 3-month initial acceptable treatment target and a 6-month optimal target, evaluated using gl
Externí odkaz:
https://doaj.org/article/f3b4e95ef131423ba2e4036632fc38b1
Autor:
Jonathan I. Silverberg, H. Chih-ho Hong, Brian M. Calimlim, Wan-Ju Lee, Henrique D. Teixeira, Eric B. Collins, Marjorie M. Crowell, Scott J. Johnson, April W. Armstrong
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 10, Pp 2247-2264 (2023)
Abstract Introduction The treatment landscape for moderate-to-severe atopic dermatitis (AD) continues to expand. This network meta-analysis (NMA) updates a previously conducted NMA to include data from the most recent phase 3 trials to assess the com
Externí odkaz:
https://doaj.org/article/a652da315a6b45c186f4bac0bdfe50c5
Autor:
Jonathan I, Silverberg, Eric L, Simpson, Brian M, Calimlim, Leighann, Litcher-Kelly, Xiaoran, Li, Xiaowu, Sun, Yael A, Leshem
Publikováno v:
Dermatology and Therapy. 12:2817-2827
Three patient-reported outcome (PRO) questionnaires-Worst Pruritus Numerical Rating Scale (WP-NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS)-were developed to assess the symptoms and impacts of atopic
Autor:
Alexandra B. Kimball, Thrasivoulos Tzellos, Brian M. Calimlim, Henrique D. Teixeira, Ziqian Geng, Martin M. Okun
Publikováno v:
Acta Dermato-Venereologica, Vol 98, Iss 10, Pp 932-937 (2018)
Hidradenitis Suppurativa Clinical Response (HiSCR), is a validated tool that has been used to assess the efficacy of adalimumab among patients with hidradenitis suppurativa. We evaluated the clinical meaning of HiSCR by relating it to patient-reporte
Externí odkaz:
https://doaj.org/article/4b528f9169e046508f3039e32cca269c
Autor:
Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati, Vivian Laquer, Alison Fischer, Samantha Eisman, Xiaofei Hu, Tianshuang Wu, Brian M. Calimlim, Blair Kaplan, Yingyi Liu, Henrique D. Teixeira, John Liu, Kilian Eyerich
Publikováno v:
Journal of the American Academy of Dermatology.
Autor:
Jonathan I, Silverberg, H Chih-Ho, Hong, Jacob P, Thyssen, Brian M, Calimlim, Avani, Joshi, Henrique D, Teixeira, Eric B, Collins, Marjorie M, Crowell, Scott J, Johnson, April W, Armstrong
Publikováno v:
Silverberg, J I, Hong, H C H, Thyssen, J P, Calimlim, B M, Joshi, A, Teixeira, H D, Collins, E B, Crowell, M M, Johnson, S J & Armstrong, A W 2022, ' Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids : Systematic Review and Network Meta-analysis ', Dermatology and Therapy, vol. 12, no. 5, pp. 1181-1196 . https://doi.org/10.1007/s13555-022-00721-1
Introduction: The comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis (AD) has not been systematically assessed using recent phase 3 data. This network meta-analysis assesses the comparative efficacy of target